PharmaEssentia: H1 2025 saw revenue and net income surge, with strong cash reserves and key legal disputes resolved
1分未満で読めます
Revenue and net income more than doubled year-over-year for H1 2025, driven by strong product sales and global expansion. Arbitration with AOP largely resolved, with most claims dismissed and some liabilities recognized. Robust cash position supports ongoing R&D and manufacturing growth.
Original document: PharmaEssentia Corp. [6446] Interim report — Aug. 28 2025
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr